Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07041983
Enrolling by invitation Observational

24-h Energy Expenditure and Anti-obesity Medication

NCT07041983 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Pisa
Phase
Observational
Started
2025-07-01
Last updated
2026-05-05

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

anti obesity medication

anti obesity medication: Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study. Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study

Study summary

This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Body mass index (BMI) \>= 30 kg/m² or \>= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months) * informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage. Exclusion Criteria: * psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation * diabetes

Primary outcome measure(s)

  • change in 24h energy expenditure after 6 months of treatment — Baseline and 6 months after treatment initiation
    measurement of 24-hour energy expenditure (kilocalories) by using the metabolic chamber (whole room indirect calorimeter) at baseline and after 6 months of treatment

Trial sites (1)

FacilityCityRegionStatus
university hospital of Pisa Pisa Italy

More University of Pisa trials in Italy

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients Recruiting
Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix Active, not recruiting
Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues Recruiting
Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients Recruiting
Evaluation of a Multimodal Tactile Feedback System for Upper Limb-loss Users: Embodiment and Performance Recruiting

Other trials for the same condition

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Recruiting
Impact of WBC on Patients With Metabolic or Neurological Diseases or Fibromyalgia (WBC-MeNeFi) Recruiting
Faesiblity and Safety of Endoscopic sLeeve gastrOplasty in Patients With obEsity and nflammatoRy Bowel Disease Recruiting
Effects of VLCKD in Metabolic Syndrome Active, not recruiting
Impact of Overweight, Obesity, and Lifestyle Changes on Work Performance and Well-Being in Medical Residents Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07041983 on ClinicalTrials.gov ↗ ← All trials in Italy